Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients
- None.
- None.
Insights
The enhancement of the Azurion Image Guided Therapy System to include a neuro biplane system signifies a noteworthy advancement in the field of neurovascular interventions. This development is poised to streamline procedures for stroke and other neurovascular diseases, which is critical given the time-sensitive nature of these conditions. The integration of advanced 2D and 3D imaging, coupled with increased flexibility in X-ray detector positioning, is expected to facilitate quicker and more accurate diagnoses, as well as more efficient treatment pathways.
From a research perspective, the availability of such a system could potentially lead to improved patient outcomes due to the precision and speed of the interventions. The ability to treat more patients efficiently not only impacts patient care but also has implications for healthcare economics by potentially reducing the length of hospital stays and the need for additional procedures.
The financial implications of stroke and other neurovascular diseases are significant, with global costs estimated at approximately $891 billion per year. The introduction of Philips' new Azurion neuro biplane system is an innovative step towards reducing these costs. By enhancing the efficiency of neurovascular procedures, this system may contribute to lowering the overall cost of care. This is particularly relevant in the context of healthcare systems that are increasingly pressured to provide high-quality care while managing expenses.
Furthermore, the system's design, which prioritizes rapid transitioning between imaging modes and comprehensive table-side control, suggests a reduction in procedure times. This efficiency not only has the potential to increase the throughput of patients but also to optimize the utilization of angio suites, which are capital-intensive resources. The long-term return on investment for healthcare providers could be substantial, considering the reduced operational costs and improved patient throughput.
The neurovascular intervention market is witnessing a growing demand for high utilization angio suites due to the rise in mechanical thrombectomy as the standard treatment for large vessel occlusion ischemic strokes. Philips' enhancements to the Azurion system, including AI and machine learning capabilities for predictive maintenance, position the company competitively within this market. The ability to predict component failures and provide proactive service is a significant value proposition that could differentiate Philips from other market players.
Moreover, the integration of the latest Neuro Suite software and services with the Azurion system exemplifies the trend towards comprehensive, connected healthcare solutions. By providing a fully integrated solution for neuro interventionists, Philips is not only addressing current clinical needs but is also aligning with the broader industry shift towards smart, connected care ecosystems that leverage data and technology to improve healthcare delivery.
February 27, 2024
New image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system. Designed to streamline neurovascular procedures and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
Minimally invasive procedures enabled by interventional systems like Azurion are a key part of the diagnosis and treatment pathway for stroke, where every minute counts in conserving the patient’s quality-of-life. Interventional systems are also used to precisely plan and carry out complex neurovascular procedures such as the repair of brain aneurysms and birth defects. By allowing neuro interventionists to treat more patients, more efficiently, with potentially better outcomes, the new Philips Azurion neuro biplane system enhances both the staff and patient experience and contributes to lower cost of care.
“Working closely with leading interventionists, we designed the latest Azurion neuro biplane to meet their requirements of superior patient care, optimized angio suite performance, and efficient return on investment,” said Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips. “Together, I am confident we can continue to reduce the impact of stroke, helping more patients to recover faster and reducing long-term impact on their health.”
Philips’ Azurion neuro biplane image-guided therapy system is designed to smooth and optimize procedure workflows where a combination of 2D and 3D imaging is needed for confident diagnosis and precision treatment. Used with the company’s latest Neuro Suite software and services, it provides neuro interventionists with a fully integrated solution that combines Philips’ world-class ClarityIQ low dose imaging with a range of neuro dedicated tools* and value-added services that offer unprecedented levels of efficiency, flexibility, and control.
New features in the Azurion neuro biplane system include enhanced C-arm rotation, angulation (imaging angles), and parking facilities that allow rapid transitioning between 2D to 3D imaging, comprehensive table-side control that eliminates the need to leave the sterile field, automatic beam rotation to obtain correctly oriented images for every angulation and rotation, and a new head immobilizer to support enhanced stroke care.
Accelerating treatment for stroke
One in four adults over the age of 25 will have a stroke at some point in their lives [1]. Globally, the direct and indirect cost has been estimated at around USD 891 billion per year [2]. The key to reducing the personal, societal, and financial impact of stroke is to follow the axiom ‘time-is-brain’. The faster stroke is treated, the better the potential outcome.
For ischemic stroke, which accounts for
In addition to the efficiency enhancing features of its Azurion platform, Philips is maximizing the up-time of its angio suite solutions by using AI and machine learning to monitor system performance through the new remote connection services of the Philips ServiceHub. These services communicate, monitor, and proactively respond to potential service issues – for example, predicting likely component failures at least 7 days in advance so that pre-emptive action can be taken.
With its comprehensive stroke care portfolio, Philips is connecting the dots between caregivers – wherever they are – at every vital step in the stroke care pathway. The result is smart stroke solutions designed to support connected care. Visit Philips at #ECR2024 for more information.
*SmartCT Soft Tissue, SmartCT Angio, SmartCT Roadmap, SmartCT Vaso, AneurysmFlow
[1] World Stroke Organization (WSO): Global Stroke Fact Sheet 2022 (https://www.world-stroke.org/assets/downloads/WSO_Global_Stroke_Fact_Sheet.pdf)
[2] Owolabi MO, Thrift AG, Mahal A, et al.; Stroke Experts Collaboration Group. Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health. 2022 Jan;7(1):e74-e85. doi: 10.1016/S2468-2667(21)00230-9. Epub 2021 Oct 29. Erratum in: Lancet Public Health. 2022 Jan;7(1):e14. PMID: 34756176; PMCID: PMC8727355. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00230-9/fulltext
[3] Virani S.S., Alonso A., Benjamin E.J., et al. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757. https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000757?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
[4] NHS England UK : https://www.england.nhs.uk/wp-content/uploads/2019/05/Mechanical-thrombectomy-for-acute-ischaemic-stroke-ERRATA-29-05-19.pdf
[5] WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment). Sponsored by Philips. https://www.wetrust-study.com/
For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
FAQ
What is the new interventional system launched by Royal Philips?
What are the key features of the new Azurion neuro biplane system?
What are the benefits of delivering intra-arterial treatment (IAT) for ischemic stroke?
How is Philips maximizing the up-time of its angio suite solutions?
What is the goal of Philips' stroke care portfolio?
